用于强直性脊柱炎的抗肿瘤坏死因子(TNF-α)抑制剂的临床应用进展

doi:10.5246/jcps.2018.01.007

中国药学(英文版) ›› 2018, Vol. 27 ›› Issue (1): 59-63.DOI: 10.5246/jcps.2018.01.007

• 【药事管理与临床药学专栏】 • 上一篇下一篇

用于强直性脊柱炎的抗肿瘤坏死因子(TNF-α)抑制剂的临床应用进展

周林光^1,2, 江滨^2*

1. 北京大学国际医院药剂科, 北京 102206
2. 北京大学医学部药学院药事管理与临床药学系, 北京 100191

收稿日期:2017-03-24 修回日期:2017-08-19 出版日期:2018-02-28 发布日期:2017-11-15
通讯作者: Tel.: +86-13601100121, E-mail: zhoulinguang@pkuih.edu.cn

Clinical development of tumor necrosis factor-alpha inhibitors for ankylosing spondylitis

Zhou Linguang^1,2, Jiang Bin^2*

1. Department of Pharmacy, Peking University International Hospital, Beijing 102206, China
2. Department of Administrative and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

Received:2017-03-24 Revised:2017-08-19 Online:2018-02-28 Published:2017-11-15
Contact: Tel.: +86-13601100121, E-mail: zhoulinguang@pkuih.edu.cn

摘要/Abstract

摘要：

抗肿瘤坏死因子(TNF-α)抑制剂是用于强直性脊柱炎的生物制剂,目前中国上市的有依那西普、英夫利昔单抗和阿达木单抗。2014–2016年这三种药物的研究进展国内尚未有系统研究,本文研究了这三种药物的新进展,主要包括: (1) 依那西普维持剂量、副反应、长期疗效、联合治疗方面; (2) 英夫利昔单抗联合治疗、对骨代谢的影响; (3) 阿达木单抗有效性、抗药抗体; (4) TNF-α抑制剂综合研究等。随着TNF-α抑制剂在临床中的广泛应用,明确其药物安全性,有效性和适用范围是指导未来临床应用,药品配伍乃至药物研发的关键。本综述总结了TNF-α抑制剂在现阶段临床应用与研究的中的进展,对今后TNF-α抑制剂的临床应用和后续研究提供了更进一步的参考和借鉴。

关键词: 强直性脊柱炎, 抗肿瘤坏死因子抑制剂, 依那西普, 英夫利昔单抗, 阿达木单抗

Abstract:

There is no radical cure for ankylosing spondylitis, a chronic inflammation in joint, till now. Tumor necrosis factor-alpha (TNF-α) inhibitors can block the cascade in inflammatory chain and improve clinical symptom. Among these biological agents, three of them are marketed in China: etanercept, infliximab and adalimumab. Some of the research progresses between 2014 and 2016 are summarized including treatment application, side effects of drugs, and comprehensive research of TNF-α inhibitors.

Key words: Ankylosing spondylitis, TNF-α, Etanercept, Infliximab, Adalimumab

中图分类号:

R954

Supporting:

周林光, 江滨. 用于强直性脊柱炎的抗肿瘤坏死因子(TNF-α)抑制剂的临床应用进展[J]. 中国药学(英文版), 2018, 27(1): 59-63.

Zhou Linguang, Jiang Bin. Clinical development of tumor necrosis factor-alpha inhibitors for ankylosing spondylitis[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(1): 59-63.

参考文献

[1] Taurog, J.D.; Chhabra, A.; Colbert, R.A. Ankylosing Spondylitis and AxialSpondyloarthritis. N. Engl. J. Med. 2016, 374, 2563-2574.

[2] Hamilton, L.; Barkham, N.; Bhalla, A.; Brittain, R.; Cook, D.; Jones, G.; Mackay, K.; Marshall, D.; Marzo-Ortega, H.; Murphy, D.; Riddell, C.; Sengupta, R.; Siebert, S.; Van Rossen, L.; Gaffney, K. BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosingspondylitis) with biologics. Rheumatology. 2017, 56, 313-316.

[3] Rheumatology, C.S. Guidelines for diagnosis and treatment of ankylosing spondylitis. Chin. J. Rheumatol. 2010, 14, 557-559.

[4] Anderson, J.J.; Baron, G.; van der Heijde, D.; Felson, D.T.; Dougados, M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis. Rheum. 2001, 44, 1876-1886.

[5] Braun, J.; van den Berg, R.; Baraliakos, X.; Boehm, H.; Burgos-Vargas, R.; Collantes-Estevez, E.; Dagfinrud, H.; Dijkmans, B.; Dougados, M.; Emery, P.; Geher, P.; Hammoudeh, M.; Inman, R.D.; Jongkees, M.; Khan, M.A.; Kiltz, U.; Kvien, T.; Leirisalo-Repo, M.; Maksymowych, W.P.; Olivieri, I.; Pavelka, K.; Sieper, J.; Stanislawska-Biernat, E.; Wendling, D.; Ozgocmen, S.; van Drogen, C.; van Royen, B.; van der Heijde, D. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 2011, 70, 896-904.

[6] Gorman, J.D.; Sack, K.E.; Davis, J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N. Engl. J. Med. 2002, 346, 1349-1356.

[7] Reed, M.R.; Taylor, A.L. Tumour necrosis factor inhibitors in ankylosing spondylitis. Intern. Med. J. 2008, 38, 781-789.

[8] NICE. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. 2016.

[9] Yates, M.; Hamilton, L.E.; Elender, F.; Dean, L.; Doll, H.; MacGregor, A.J.; Thomas, J.; Gaffney, K. Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial. J. Rheumatol. 2015, 42, 1177-1185.

[10] Ye, Y.J.; W, C.C.; Qiu, Q.; Liang, L.Q. Maintenance of the therapeutic efficacy of etanercept in active ankylosing spondylitis patients when tapering its dosage. J. Practical. Med. 2016, 32, 2642-2645.

[11] Bessant, R.; Keat, A. How should clinicians manage osteoporosis in ankylosing spondylitis? J. Rheumatol. 2002, 29, 1511-1519.

[12] Li, H.; Li, Q.; Chen, X.; Ji, C.; Gu, J. Anti-tumor Necrosis Factor Therapy Increased Spine and Femoral Neck Bone Mineral Density of Patients with Active Ankylosing Spondylitis with Low Bone Mineral Density. J. Rheumatol. 2015, 42, 1413-1417.

[13] Arends, S.; Brouwer, E.; Efde, M.; van der Veer, E.; Bootsma, H.; Wink, F.; Spoorenberg, A. Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice. Clin. Exp. Rheumatol. 2017, 35, 61-68.

[14] Jin, Q. Clinical observation of 90 cases of etanercept combined with Cloud G treatment of ankylosing spondylitis. J. Clin. Med. Pract. 2016, 20, 153-154.

[15] Ke, L. Clinical efficacy of etanercept combined with sulfasalazine in treatment of ankylosing spondylitis. Guide China Med. 2014, 12, 217-218.

[16] Sieper, J.; Lenaerts, J.; Wollenhaupt, J.; Rudwaleit, M.; Mazurov, V.I.; Myasoutova, L.; Park, S.; Song, Y.; Yao, R.; Chitkara, D.; Vastesaeger, N. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis, results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum. Dis. 2014, 73, 101-107.

[17] Lei, J.; Li, Z. Jia qiong. Clinical observation of 30 cases of Modified Simiao Pills combined with infliximab in the treatment of ankylosing spondylitis. Guid. J. Traditional Chin. Med. Pharm. 2015, 21, 74-76.

[18] Xiao, Y.Y.; Zhang, J.; Qiu, X.; Zhong, L.; Xiao, X.; Zhang, Y.Y.; Xie, J.J. Observation of the efficacy of infliximab and Bushen Tongbitai granules in the treatment of ankylosing spondylitis. Neimonggu J. Tradit. Chin. Med. 2015, 8, 62-63.

[19] Jia, J.T.; Wang, H.; Li, H.; Xue, X.P. Effect of Inflximab on Bone Metabolic Indices in Ankylosing Spondylitis. Chin. J. Allergy Clin. Immunol. 2014, 8, 278-282.

[20] Mease, P.; Sieper, J.; Van den Bosch, F.; Rahman, P.; Karunaratne, P.M.; Pangan, A.L. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol. 2015, 67, 914-923.

[21] Huang, F.; Gu, J.; Zhu P, Bao, C.; Xu, J.; Xu, H.; Wu, H.; Wang, G.; Shi, Q.; Andhivarothai, N.; Anderson, J.; Pangan, A.L. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis, results of a randomised, controlled trial. Ann Rheum. Dis. 2014, 73, 587-594.

[22] Paramarta, J.E.; Baeten, D.L. Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation. Arthritis Res. Ther. 2014, 16,

[23] Cantini, F.; Niccoli, L.; Goletti, D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J. Rheumatol. (Suppl.) 2014, 91, 47-55.
[24] Maxwell, L.J.; Zochling, J.; Boonen, A.; Singh, J.A.; Veras, M.M.; Tanjong Ghogomu, E.; Benkhalti Jandu, M.; Tugwell, P.; Wells, G.A. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane. Database Syst. Rev. 2015, 18, 23-30.

用于强直性脊柱炎的抗肿瘤坏死因子(TNF-α)抑制剂的临床应用进展

Clinical development of tumor necrosis factor-alpha inhibitors for ankylosing spondylitis

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	董志勇, 邱仙土, Stacy A. Kujawa, S.M. Shariful Islam, 张杰. 华蟾素注射液治疗中晚期原发性肝癌的统评价和Meta分析[J]. 中国药学(英文版), 2019, 28(4): 264-275.
[2]	陈敏, 姜锋, 郑铭, 阳丽梅, 高红瑾. 基于APICloud 的药物基因组用药指导信息的手机APP的设计与实现[J]. 中国药学(英文版), 2019, 28(4): 276-283.
[3]	张琪, 张博, 林能明. 基于伊马替尼治疗系统性硬化症疗效的meta分析[J]. 中国药学(英文版), 2019, 28(3): 195-202.
[4]	卢新璞, 郭志刚, 傅孟元, 海沙尔江·吾守尔, 史录文, 管晓东. 中国基本药物制度对合理用药的影响: 基层医疗机构横断面研究[J]. 中国药学(英文版), 2019, 28(1): 49-55.
[5]	张弨, 谢若函, 王楚慧, 袭辰辰, 戈梦佳. 基于群体药动学和药效学的仿真对肾功能不全病人使用哌拉西林/他唑巴坦进行剂量优化[J]. 中国药学(英文版), 2018, 27(12): 824-831.
[6]	管晓东, 马莉莉, 王国英, 海沙尔江·吾守尔, 满春霞, 韩晟, 史录文. 中国2型糖尿病患者胰岛素注射笔用针头重复使用的影响因素研究[J]. 中国药学(英文版), 2018, 27(1): 51-58.
[7]	赵德华, 楚明明, 陈静, 王继生. 吉西他滨标准剂量30分钟快速输注与低剂量延时输注治疗进展期非小细胞肺癌的Meta分析[J]. 中国药学(英文版), 2017, 26(10): 763-770.
[8]	蔡彤, 裴宇盛, 张国来, 陈晨, 高华. 第8批细菌内毒素国家标准品的建立[J]. 中国药学(英文版), 2017, 26(10): 771-774.
[9]	王利群, 谢晓慧, 周瑞瑞. 我国大陆期刊哮喘药学服务随机对照研究的质量评价[J]. 中国药学(英文版), 2017, 26(3): 212-221.
[10]	林洁莹, 刘京京, 齐亚宁, 王春明. 含吗啡中成药的滥用风险研究[J]. 中国药学(英文版), 2017, 26(2): 139-146.
[11]	韩茹, 安雅晶, 赵荣生. α-酮酸对慢性肾脏病患者的附加作用: 一项随机对照试验的系统评价和meta分析[J]. 中国药学(英文版), 2017, 26(1): 63-75.
[12]	刘园园, 梁舒瑶, 陈恳, 张帆, 刘芳. 伏立康唑对联合使用药物的药代动力学和安全性的影响: 系统评价[J]. 中国药学(英文版), 2016, 25(11): 785-798.
[13]	Mostafa Essam Eissa. Study of parameters affecting infection risk from contaminated injectable products using multiple spot contamination model: a case study of insulin vials[J]. 中国药学(英文版), 2016, 25(11): 832-837.
[14]	聂小燕, 胥洋, 扶宇, 李俊蕾, 梁广楷, 张涌, 陆芸, 刘健, 史录文. 光学比浊法和血栓弹力图法用于判断急性冠脉综合征患者氯吡格雷药物反应性的相关性和一致性对比研究[J]. 中国药学(英文版), 2016, 25(11): 838-845.
[15]	马卓, 崔向丽, 刘丽宏. 硫酸镁治疗成人哮喘急性发作的系统评价[J]. 中国药学(英文版), 2016, 25(8): 621-631.